AIP
BIIB icon

Arrowpoint Investment Partners’s Biogen BIIB Stock Holding History

Arrowpoint Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,200
Closed -$848K – 159
2025
Q1 		$848K Buy
+6,200
New +$886K 0.1% 239

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arrowpoint Investment Partners's BIIB Position: Q1 2026 in Review

Arrowpoint Investment Partners increased its Biogen (BIIB) stake by 65% in Q1 2026, buying an estimated $341K and bringing the position to 4,706 shares worth $863K. The position accounts for 0.77% of the portfolio, ranked #28.

Arrowpoint Investment Partners first reported a position in BIIB in Q1 2025 and has held it in 3 quarters since. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Arrowpoint Investment Partners held 4,706 shares of Biogen worth $863K as of Q1 2026.
  • Arrowpoint Investment Partners bought 1,851 Biogen shares in Q1 2026, an estimated $341K.
  • Biogen made up 0.77% of Arrowpoint Investment Partners's portfolio in Q1 2026, its #28 holding.
  • Arrowpoint Investment Partners first reported a position in Biogen in Q1 2025 and has held it in 3 quarters since.
  • 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.